Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Johnson & Johnson’s nasal spray for depression wins FDA panel backing

A U.S. FDA advisory panel voted in favor of J&J’s experimental nasal spray esketamine, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.

Read More »

FDA Rejects Alkermes’ Opioid Modulator Treatment for Depression

The U.S. FDA rejected marketing approval of Alkermes’ major depressive disorder treatment ALKS-5461.

Read More »

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc. and France’s Sanofi SA.

Read More »

Depression treatment fails to get FDA panel backing

An FDA advisory panel voted against approving Alkermes Plc’s depression treatment ALKS 5461 in patients with an inadequate response to standard antidepressant therapies.

Read More »

U.S. FDA panel backs Celltrion biosimilar

An advisory panel to the U.S. Food and Drug Administration voted unanimously in favor of Celltrion Pharm Inc.’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.

Read More »

FDA staff says AcelRx opioid painkiller is not better than rivals

AcelRx Pharmaceuticals Inc.’s opioid painkiller offers no apparent advantage to currently available therapies, staff reviewers of the U.S. Food and Administration said.

Read More »

FDA Advisory Panel Supports Paratek’s Investigational Antibiotic, PDUFA Set for October

Shares of Paratek Pharmaceuticals climbed in pre-market trading after the company announced a U.S. Food and Drug Administration advisory committee voted overwhelmingly in favor of intravenous and oral treatments for acute bacterial skin and skin structure infections (ABSSSI).

Read More »

FDA panel votes against approval of GSK’s lung disease drug

A U.S. Food and Drug Administration expert panel did not support approval of GlaxoSmithKline Plc’s drug Nucala in treating a disease that limits airflow to the lungs.

Read More »

FDA raises efficacy doubts on GSK lung disease drug

U.S. Food and Drug Administration staff reviewers raised doubts over the effectiveness of GlaxoSmithKline Plc’s drug Nucala in treating a disease that limits airflow to the lungs.

Read More »

FDA Panel Backs Indivior’s Opioid Addiction Drug

The U.S. FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-to-1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom